Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Multicenter, Double-Blind Study to Evaluate the Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects in Japan With Moderate to Severe Atopic Dermatitis

Trial Profile

A Phase 3 Randomized, Multicenter, Double-Blind Study to Evaluate the Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects in Japan With Moderate to Severe Atopic Dermatitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Feb 2019

At a glance

  • Drugs Upadacitinib (Primary) ; Corticosteroids
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Registrational
  • Sponsors AbbVie
  • Most Recent Events

    • 11 Feb 2019 Planned End Date changed from 8 May 2022 to 21 Feb 2022.
    • 19 Nov 2018 Planned End Date changed from 8 Jun 2022 to 8 May 2022.
    • 19 Nov 2018 Planned primary completion date changed from 21 Dec 2019 to 14 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top